Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg

Metformin, the active ingredient in Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg, is a biguanide presented as a 1000 mg/50 mg tablet for oral use. It helps control blood glucose levels in adults with type 2 diabetes mellitus, often in combination with other antidiabetic agents to achieve glycemic targets.

GNH USA supplies Metformina + Sitagliptina Pharmazac 50 Mg/1000 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and research institutions, ensuring consistent quality and regulatory compliance across markets.

Metformina + Sitagliptina Pharmazac is indicated for management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose. - Inadequate response to metformin alone: provides additional glucose reduction through DPP‑4 inhibition. - Combination therapy with diet and exercise: assists in achieving target HbA1c when lifestyle measures are insufficient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headaches. - Upper respiratory infection: nasopharyngitis symptoms. - Hypoglycemia (when combined with insulin or sulfonylureas): dizziness or sweating.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: jaundice, elevated liver enzymes. - Renal impairment: worsening kidney function, especially with dehydration.

Before initiating therapy, evaluate renal and hepatic function and consider patient‑specific risk factors.

- Renal function: assess eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment. - Hypoglycemia: monitor closely when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Cardiovascular status: exercise caution in patients with heart failure. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Metformina + Sitagliptina Pharmazac may interact with several medicines; review patient medication lists regularly.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Iodinated contrast media: potential renal dysfunction with metformin. - Cimetidine: may raise metformin plasma levels. - Strong CYP3A4 inhibitors: can increase sitagliptin exposure. - Alcohol abuse: heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Rifampin: may reduce sitagliptin concentrations. - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazolidinediones: additive risk of fluid retention.